Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.98%
As of Friday, August 28, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.98%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.01%
As of Thursday, July 23, Revolution Medicines, Inc.’s RVMD share price has surged by 5.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Up 6.57%
As of Thursday, June 25, Revolution Medicines, Inc.’s RVMD share price has surged by 6.57%, which has investors questioning if this is right time to sell.Michael Rose
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.15%
As of Wednesday, June 10, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.84%
As of Tuesday, June 02, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.84%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42,837.3 | $261.1 | 92% |
|
| Shares Out (Mil) | 210.9 | 54.3 | 77% |
|
| Institutional Ownership | 97.6% | 92.9% | 74% |
|
| Float (Mil) | 184.5 | 41.5 | 72% |
|
| Beta | 1.41 | 0.95 | 80% |
|
| Avg Daily Volume (000s) | 2,467 | 677 | 83% |
|
| Price Change (52-week) |
352.1% | 51.8% | 99% |
|
| Growth | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (59.9%) | (10.1%) | 5% |
|
| EPS (5yr) | (24.2%) | 15.8% | 11 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (20.3%) | (15.6%) | 33% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 19 | 21 | 21 | |
| Current EPS | ($2.401) | ($9.703) | ($6.116) | |
| Month Ago EPS | ($2.455) | ($9.661) | ($6.594) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.970) | ($8.005) | ($5.703) | |
| Year/Year Chg | (21.4%) | 63.1% | (53.9%) | |
| Financials | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($1,768) | ($43) | 1% |
|
| EPS (TTM) | ($8.921) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($1,223) | ($32) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $414 | $2 | 89% |
|
| Long-Term Debt (Q1) (Mil) | $1,174 | $4 | 68% |
|
| Enterprise Value (Q1) (Mil) | $38,180 | $174 | 90% |
|
| Valuation | RVMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 16.44 | 2.52 | 94% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (52.4%) | (47.5%) | 11% |
|
| ROE | (79.1%) | (54.9%) | 11% |
|
| Liabilities to Assets | 39.7% | 29.4% | 30% |
|
| F-Score | 1 | 3 | 1% |
|
Revolution Medicines, Inc. did not pass any screens on 9/24/2026.
